Payments for Development. In consideration of the Development to be carried out by DURA during the term of this Agreement, Xxxxxx Corp. II shall reimburse DURA out of Available Funds for all of (a) the Direct Development Costs plus a fee equal to twenty-five percent (25%) of all of such costs (the "Management Fee"), PROVIDED that the cost to DURA of services provided by Affiliates of DURA shall not exceed the cost to each Affiliate of providing such services, and (b) the Indirect Development Costs plus a fee equal to twenty percent (20%) of all such costs (the "Indirect Management Fee"), invoiced to Xxxxxx Corp. II
Payments for Development. (a) In consideration of EURAND’s performance in accordance with the terms and conditions of this Agreement, RELIANT shall make the payments (non refundable to RELIANT) to EURAND in accordance with the payment schedules set forth in Exhibit A hereto.
(b) In addition to the payments set forth on Exhibit A hereto, RELIANT shall be responsible for the following additional materials, development costs and/or expenses:
(i) The cost of any additional development or registration work performed by EURAND at the request of RELIANT, above and beyond the defined and intended scope of work of the Development Program;
(ii) A process fee for each validation batch of Product at a cost of EURAND’s manufacturing cost (as defined in the Exhibit C) for Product + [***] %;
(iii) The cost of any bio-studies approved in advance by RELIANT and performed in conjunction with the Development Program; and
(iv) The reasonable out of pocket expenses associated with travel of EURAND personnel associated with the Development Project, such expenses having been previously authorized by RELIANT. [***]: Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Payments for Development. As consideration for the development of the Design Specifications and the discharge of all of TRX’s obligations related to the Development Services, WORLDTRAVEL agrees to pay TRX a fee as follows (the “Development Fee”):
8.10.1 The Development Fee shall be based on the work specified in the Delivery Order, calculated at rates *. An estimate of the actual Development Fee shall be set forth in the Delivery Order. The Development Fee shall not exceed the estimate in the Delivery Order by more than *, without written authorization from WORLDTRAVEL.
8.10.2 The Development Fee will be paid in * in accordance with the payment schedule set forth in the Delivery Order, and each * shall be payable upon completion of each milestone by TRX and acceptance by WORLDTRAVEL in accordance with Sections 2 and 3 of Exhibit E, Development Procedures. The Market Rates payable hereunder shall be effective for the *.
Payments for Development. (a) In consideration of EURAND’s performance in accordance with the terms and conditions of this Agreement, ECR shall make the payments (non-refundable to ECR) to EURAND as shown in Exhibit D hereto.
(b) In addition to the payments referenced in paragraph (a) above, ECR shall be responsible for the following additional materials, development costs PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. and/or expenses to the extent they are not covered in the Development Plan:
(i) The cost of any development or registration work performed by EURAND at the request of ECR, above and beyond the defined work of the Development Program;
(ii) The cost of any bio-studies performed in conjunction with the Development Program;
(iii) The reasonable, ordinary and necessary expenses associated with travel of EURAND personnel in connection with the Development Project; provided, however, that such travel has been authorized by ECR in advance and in writing; and
(iv) Active Ingredient costs.
Payments for Development. In consideration of Elite’s performance with the terms and conditions of this agreement, {***} shall pay Elite for the development work according to the terms outlined in exhibit B.
Payments for Development. (a) In consideration of Elite’s performance in accordance with the terms and conditions of the Agreement, Hi-Tech shall pay Elite’s fees for the Development Program according to the terms outlined in Schedule B of this agreement. The payments described in Schedule B shall be made in advance, following completion of each phase, and prior to commencing work on the next phase. Elite shall provide written notice of its intent to commence each phase, and Hi-Tech shall pay Elite’s fee for such phase within fifteen (15) days after receipt of such notice, unless Hi-Tech elects to terminate the Agreement pursuant to Section 9.4. The initial payment shall be made when Elite notifies Hi-Tech that it intends to commence the Development Program. Any costs in excess of the amount outlined in Schedule B must be approved in writing in advance by Hi-Tech. Any out-of-pocket-expenses including raw material costs will be paid for by Hi-Tech. Costs for filing of the DMF per Section 2.3 and any additional work mutually agreed upon by the Parties, but not covered in Schedule B shall be paid for at cost. Elite will invoice Hi-Tech for these costs and provide details of the work completed and suppliers’ invoices as documentation of the costs. Costs over $1,000 will be pre-approved in writing by Hi-Tech. Hi-Tech shall pay within 30 days any invoice from Elite with respect to any approved expenses incurred in developing the Intermediate Product.
(b) In addition to the developmental work outlined, Hi-Tech will pay the cost of stability studies and any bio-studies and any analyses associated with such bio-studies which are performed in conjunction with the Development Program.
(c) Any payments earned in accordance with Schedule B shall not be refundable.
Payments for Development. In consideration of Elite’s performance with the terms and conditions of this agreement, Mikah shall pay Elite for the development work according to the terms outlined in exhibit B, items 1,2 and 3, of this agreement.
Payments for Development. As partial consideration for the development of Inventions and Technology and the Collaborative Screens to be developed by Aurora or by Aurora and Merck, Merck shall pay *** per year for a period of *** beginning on the Effective Date for such development. The fully-burdened rate for each Aurora full time equivalent shall *** per year based on a minimum *** per year, annually increased on the anniversary of the Effective Date to reflect adjustment in the CPI, using January 1, 1997 as the base year (a "FTE"). Such payments shall be payable in quarterly payments ***, the first payment to be made on or before the first January 15, April 15, July 15 or October 15 occurring after the Effective Date and the subsequent Nineteen (19) such quarterly payments made every three months thereafter. Such payments shall be non-refundable and non-creditable. In no event shall Merck be obligated to pay more than *** under this Section 3.1.1.5 per year of the Collaborative Period. The parties acknowledge that the total number of FTEs may be reduced due to CPI adjustment. Of the Aurora FTEs funded by Merck, Aurora will dedicate three (3) FTEs to ***. All other FTEs each year will be allocated from a pool of Aurora personnel resources that will contain individuals that may have expertise or experience that can be applied to a particular Collaborative Screen, new instrumentation or new reporter. The parties understand and agree that Aurora is not obligated to enter into a CSP Work Plan where more than two (2) FTEs for one year would reasonably be needed to complete the work under such CSP Work Plan.
Payments for Development. (a) In consideration of EURAND's performance in accordance with the terms and conditions of this Agreement as defined in Exhibit A, GLOBAL shall make the following payments to EURAND:
(I) Upon execution of this Agreement $100,000.00
Payments for Development. (a) In consideration of EURAND’s performance in accordance with the terms and conditions of this Agreement, RELIANT shall make the payments (non refundable to RELIANT) to EURAND in accordance with the payment schedules set forth in Exhibit A hereto.
(b) In addition to the payments set forth on Exhibit A hereto, RELIANT shall be responsible for the following additional materials, development costs and/or expenses:
(i) The cost of any additional development or registration work performed by EURAND at the request of RELIANT, above and beyond the defined and intended scope of work of the Development Program; PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.
(ii) A process fee for each validation batch of Product at a cost of EURAND’s manufacturing cost (as defined in the Exhibit C) for Product [**];
(iii) The cost of any bio-studies approved in advance by RELIANT and performed in conjunction with the Development Program; and
(iv) The reasonable out of pocket expenses associated with travel of EURAND personnel associated with the Development Project, such expenses having been previously authorized by RELIANT.
